Recent Updates
Recently added Catalysts

Lamictal

Phase 1

Healthy | Small molecule | Other |Teva Pharmaceutical Industries Limited|Last Updated: Aug 19, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials2
Total Enrollment64

FDA Designations

No designations recorded

Clinical trial landscape

Lamictal · 2 trials · 1 indication

Phase 1 2
NCT00834561Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting ConditionsHealthy
COMPLETED32 Analytics
NCT00835263Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting ConditionsHealthy
COMPLETED32 Analytics
PHASE1COMPLETED
Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions
HealthyUnlock trial analytics
PHASE1COMPLETED
Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Cmax - Maximum Observed Concentration
Blood samples collected over 120 hour period

Bioequivalence based on Cmax

AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
Blood samples collected over 120 hour period

Bioequivalence based on AUC0-inf

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
Blood samples collected over 120 hour period

Bioequivalence based on AUC0-t

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
LamotrigineEXPERIMENTALLamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
Lamictal®ACTIVE_COMPARATORLamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period

Interventions

NameTypeDescription
LamotrigineDRUG200 mg Tablet
Lamictal®DRUG200 mg Tablet
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria * Subjects will be females and/or males, non-smokers, 18 years of age and older. * Female Subjects will be post-menopausal or surgically sterilized. * Post-menopausal status is defined as absence of menses for the past 12 months, * Sterile status is defined as hysterectomy, bilat...

Countries:Canada
Unlock Eligibility Criteria

Frequently asked questions about Lamictal

What is Lamictal used for?

Lamictal, also known as lamotrigine, is being studied in healthy volunteers in Phase 1 clinical trials. These trials are bioequivalence studies of a 200 mg lamotrigine tablet under fasting and non-fasting conditions. The drug is not approved for any specific indication based on the available data.

Who makes Lamictal?

Lamictal is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting Phase 1 clinical trials to evaluate the bioequivalence of a 200 mg lamotrigine tablet in healthy volunteers.

What phase is Lamictal in?

Lamictal is in Phase 1 clinical development. It is an investigational drug being studied in healthy volunteers for bioequivalence purposes. It has not been approved by regulatory authorities, and it remains in early-stage clinical trials.

What clinical trials is Lamictal in?

Lamictal is involved in two completed Phase 1 clinical trials: NCT00834561, a bioequivalence study of a 200 mg lamotrigine tablet under fasting conditions, and NCT00835263, a similar study under non-fasting conditions. Both trials enrolled 32 healthy volunteers each in Canada.

Is Lamictal the same as lamotrigine?

Yes, Lamictal is the brand name for lamotrigine. The clinical trials for Lamictal are specifically studying a 200 mg lamotrigine tablet, confirming that Lamictal and lamotrigine refer to the same drug substance.